Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review
What's next for RADx? The NIH drafts a to-do list for its $1.5B diagnostics competition, through COVID and beyond
Despite rough start, Biogen's Aduhelm should find footing, analysts say. But don't expect much in 2021
Mirum gets iBAT inhibitor Livmarli across the FDA finish line for rare pediatric liver condition
How exploiting a protective gene mutation might protect the brain from Alzheimer's disease
Health systems-backed Truveta lands investment from Microsoft, cloud partnership
Biotech incubator Sporos' new CEO arrives from Ovid with Biogen, Bristol Myers experience
FDA alerts HCPs to higher risk for women with stroke-preventing heart implant
AMA: 73% of health insurance markets are highly concentrated

Thank you to IQVIA Biotech for sponsoring Fierce Biotech's
2021 Fierce 15 editorial feature.

Featured Story

Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review

By Dave Muoio

The Massachusetts system's decision not to provide Biogen's Aduhelm to patients follows a review by its internal expert panel. It comes after other big-name providers and payers said they would not support the treatment earlier this summer.

What's next for RADx? The NIH drafts a to-do list for its $1.5B diagnostics competition, through COVID and beyond

By Andrea Park

During a panel discussion about the initiative at AdvaMed’s annual MedTech Conference, the NIH's Bruce Tromberg outlined what’s next for RADx, which was launched as a “Shark Tank”-like competition to develop COVID tests as quickly as possible.

Despite rough start, Biogen's Aduhelm should find footing, analysts say. But don't expect much in 2021

By Eric Sagonowsky

As Biogen's new Alzheimer's drug Aduhelm makes headlines nearly every day—many covering the drug's slower-than-expected uptake—one team of biopharma analysts is lowering their 2021 expectations for the med. Nonetheless, despite the drug sputtering out the gate, the team still sees a multibillion-dollar sales opportunity for the company in Alzheimer's disease.

Mirum gets iBAT inhibitor Livmarli across the FDA finish line for rare pediatric liver condition

By Kevin Dunleavy

Mirum Pharmaceuticals of California has taken Livmarli, a minimally absorbed ileal bile acid transporter (iBAT) inhibitor, across the FDA finish line. The drug =m which is taken in capsule form, is the first medication approved for the cholestatic pruritus which which accompanies the rare liver disorder Alagille syndrome.

How exploiting a protective gene mutation might protect the brain from Alzheimer's disease

By Angus Liu

A mutation in the APOE3 gene increases the formation of fatty molecules that are critical for preserving nerve cell functioning and that may reduce the toxic aggregation of protein clumps in the brain, a Mayo Clinic team has found. Targeting this process with drugs could protect against Alzheimer's disease, they suggested.

Health systems-backed Truveta lands investment from Microsoft, cloud partnership

By Heather Landi

Healthcare data startup Truveta inked a deal with Microsoft to build a clinical data platform on the cloud. The software giant also is investing an undisclosed amount in Truveta, which is backed by 17 healthcare systems, including Providence, Novant Health, Northwell Health and Trinity Health.

PM Tracker

Featured Story

Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review

Top Stories

What's next for RADx? The NIH drafts a to-do list for its $1.5B diagnostics competition, through COVID and beyond

Despite rough start, Biogen's Aduhelm should find footing, analysts say. But don't expect much in 2021

Mirum gets iBAT inhibitor Livmarli across the FDA finish line for rare pediatric liver condition

How exploiting a protective gene mutation might protect the brain from Alzheimer's disease

Health systems-backed Truveta lands investment from Microsoft, cloud partnership

Biotech incubator Sporos' new CEO arrives from Ovid with Biogen, Bristol Myers experience

FDA alerts HCPs to higher risk for women with stroke-preventing heart implant

AMA: 73% of health insurance markets are highly concentrated